Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

MTH1, A Phase I, Study on Tumors Inhibition, First in Human, First in Class

NCT03036228 is registered in ClinicalTrials.gov with Thomas Helleday Foundation as lead sponsor.

NCT NCT03036228
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03036228 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
MTH1, A Phase I, Study on Tumors Inhibition, First in Human, First in Class
Lead sponsor
Thomas Helleday Foundation
Phase
Phase 1
Overall status
Completed
Start date
January 14, 2017
Completion date
December 17, 2024
Enrollment
63 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

cancer